18 results about "Pathologic" patented technology

Systems and methods for the improved quantitative assessment of airway mucus plug pathology are provided herein which provide a quantitative suite of mucus imaging metrics that objectively quantifies features of mucus plug pathology in the lungs. Systems and methods for generating a subject-level mucus plug map that illustrates the position of one or more whole mucus plugs, or the absence of mucus plugs in an airway tree are discussed. Systems and methods for the determination of a subject-level mucus plug phenotype are provided herein.

The present disclosure relates to a method of treating, preventing or delaying an age-related condition or pathology in a mammal using extracellular vesicles (EVs) derived from a young mammal.

Described herein are EphA4 receptor antagonists, pharmaceutical compositions containing EphA4 antagonists, and methods and uses of treating an EphA4-based disease, disorder or pathology in an individual using EphA4 receptor antagonists.

Described herein are various embodiments of techniques for determining reference values / ranges for diagnostic markers for patients during treatment and recovery during and / or after illness or injury. Some methods may include obtaining a patient's medical information (including any diagnosed medical conditions) and calculating, based on the medical condition and an elapsed time since onset or start of treatment, expected reference ranges for one or more diagnostic markers. These methods may also include outputting an indication of whether the measurements for the diagnostic marker or markers fall outside the reference range(s). In some embodiments, the reference values can be adjusted depending on additional pathologies indicated in the patient's medical information. Some such patient- and / or pathology-specific reference values / ranges can also be displayed to medical professionals to aid in patient care and / or leveraged in automated patient monitoring systems to alert doctors that a patient is not recovering according to the expected trajectory.

The present application discloses, as an embodiment of the invention, a compound, or a pharmaceutically acceptable salt thereof, that is useful as an agent for preventing or treating a disease caused by a decrease in autophagy function or a disease in which a pathological condition is suppressed or improved by the enhancement of autophagy function, and that is represented by formula (I) (in formula, the symbols are as described in the specification).

The present invention relates to compounds and compositions for use in a method of treating and / or preventing neurological or non-neurological channelopathies, i.e., pathologies which are caused specifically by defects in some of the calcium-activated potassium channels. Specific neurological channelopathies and / or synaptopathies targeted by the present invention include specific neuropsychiatric pathologies, such as particularly Fragile X Syndrome (FXS), Angelman syndrome, Williams-Beuren syndrome, autism, Autism spectrum disorders (ASDs), hyperacusis, Smith-Magenis syndrome, Prader-Willi syndrome, 7q11.23 duplication syndrome, and cri-du-chat syndrome, as well as other neuropathic disorders such as trembling, epilepsy and neuropathic pains associated and neurodegenerative diseases such as Parkinson's and Alzheimer diseases. Compounds, compositions and methods of the present invention are also particularly useful and efficient in alleviating neurological symptoms common to these neuropsychiatric pathologies.

The present disclosure generally relates to compositions and methods to increase resistance to age-related pathologies, improve physiological state or disorder related to cell ageing or metabolic fatigue in one or more cells; improve mobility and / or healthspan and / or lifespan of an adult animal in need. More specifically, the present disclosure relates to administering a formulation comprising an effective amount of nicotinamide (NAM) and Glycine, optionally an autophagy inducer.

The present disclosure relates to a method for generating a trained classifier adapted to detect a targeted pathology in a body fluid sample, the method comprising: processing a set of body fluid samples each being associated with a presence indicator of the targeted pathology, to obtain processed samples each comprising a list of exRNAs comprising values representative of occurrence numbers of the exRNAs, detected in the body fluid sample; training machine learning models using the processed samples and a presence indicator of the targeted pathology associated with the processed samples; testing the trained machine learning models; generating a list of selected exRNA as a function of the scores attributed by the trained machine learning models; and training a classifier using the processed samples and the presence indicator of the targeted pathology, the trained classifier and the list of selected exRNA being used to detect the targeted pathology.

Methods and systems for automatic classification, detection, assessment, and / or diagnosis of a pathology in a subject determine presence or absence, and / or a severity of various pathologies in a subject, for example, presence, absences, and / or severity of aortic stenosis in a heart of a subject.

Described herein are methods of making and using a transgenic mouse model of Alzheimer's disease. Transgenic animal models and cell lines are disclosed for the study of Alzheimer's disease or Alzheimer's disease-type pathology. Methods of screening and identifying active agents for the treatment of Alzheimer's disease or Alzheimer's disease-type pathology are also provided.

This application provides a method, electronic device, and medium for generating a disease diagnosis plan. The method includes: acquiring symptoms input by a user; obtaining macro nodes with semantically identical to the symptoms, and macro links where the macro nodes with semantically identical to the symptoms are located, based on the macro subnet; determining, based on the meso subnet, a meso node matching the macro node at the starting position of the macro link, and a meso link where the matching meso node is located, wherein the matching meso node represents the pathology of the symptoms; determining, based on the micro subnet, a micro node matching the meso node at the starting position of the meso link, and a micro link where the matching micro node is located, wherein the matching micro node represents the molecular information of the pathology; and determining a diagnosis plan based on the micro link, the meso link, and the macro link.

Disclosed herein are antibodies or antigen-binding fragments thereof and compositions comprising the same. Also disclosed are methods of detecting TAR DNA-binding protein 43 (TDP-43) in a biological sample, diagnosing a neurodegenerative disease in a subject, and selecting whether to enroll a subject in a clinical trial for frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) using the antibodies or antigen-binding fragments thereof described herein. In addition, disclosed herein are immunoassay kits for selectively detecting TDP-43 in a biological sample.

The invention provides a Parkinson's disease auxiliary diagnosis kit based on an RT-QuIC technology and application of the Parkinson's disease auxiliary diagnosis kit, and belongs to the technical field of detection kits. The kit provided by the invention has remarkable minimally invasive property and high patient compliance, detection can be completed only by collecting trace skin tissues, and risks and pains of lumbar puncture or brain tissue biopsy are avoided. The kit has excellent detection performance, can realize highly sensitive and specific identification of early pathology of Parkinson's disease, has a fast detection process, can complete batch sample analysis in a short time, and powerfully supports clinical rapid diagnosis and screening requirements. Meanwhile, the overall cost is remarkably lower than that of existing methods such as imaging, a convenient, reliable and economical molecular detection means is provided for early discovery, clinical auxiliary diagnosis and treatment effect observation of the Parkinson's disease, and positive significance is achieved for improving the overall diagnosis and treatment level of the neurodegenerative diseases.

The present disclosure provides a compound of Formula I which are naphthalene monoimide compounds, and process of preparing thereof. The compounds of the present disclosure provide reversal of cognitive decline or improvement of cognitive decline. The compounds of Formula (I) of the present disclosure synergistically modulate metal independent and dependent amyloid toxicity, scavenge reactive oxidative species (ROS), alleviate oxidative stress, emulate Nrf2 mediated stress response, mitochondrial damage, microglial activation and neuroinflammation.

The present invention is directed to a novel therapeutic strategy for treating a disease mediated by copper, by inhibiting the function of cellular prion protein (PrP).

This application discloses a nonlinear survival risk modeling method based on pathology after neoadjuvant chemotherapy for gastric cancer. The method includes: acquiring pathological data and follow-up data of patients after neoadjuvant chemotherapy, wherein the pathological data includes at least the number of lymph nodes dissected, the number of positive lymph nodes, the pathological T stage after treatment, and the tumor regression grade; performing legality checks, missing data handling, scaling transformation, and ordered encoding on the pathological data to generate case feature vectors; constructing locally comparable sample pairs based on the case feature vectors to generate a set of local monotonic constraints; inputting the case feature vectors, follow-up data, and the set of local monotonic constraints into a Gaussian process enhanced Cox model for training to obtain a continuous risk function; generating a continuous risk surface based on the continuous risk function, extracting and screening stable contour boundaries, and then determining the contour-based ypTNM risk stratification label of the case to be evaluated.

A method is provided for synthesizing images containing pathologies for training a discriminative prediction algorithm for performing pathology detection and diagnosis. The method includes randomly selecting a negative image showing no pathology from a dataset of negative images; identifying a location of an anatomical landmark in the negative image; determining a desired location for placing a pathology to be simulated in the negative image based on the anatomical landmark; generating a binary mask image based on the desired location for the pathology, the binary mask image including a basic structure of the pathology to be simulated at the desired location; selecting an image pair including the negative image with a masked out area and the binary mask image; and generating a synthesized image based on the image pair, where the synthesized image includes a synthesized background corresponding to the negative image and a synthesized foreground corresponding to the basic structure of the pathology to be simulated in the binary mask image at the masked out area in the negative image.